152: Long Term Remission in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients After Allogeneic Myeloablative Hematopoietic Cell Transplantation (HCT) Using Matched Related Donors: The 20 Year Experience at Stanford University and City of Hope National Medical Center

G.G. Laport, J.C. Alvarnas, J.M. Palmer, D.S. Snyder, M.L. Slovak, A.M. Cherry, R.S. Negrin, K.G. Blume, S.J. Forman
2008 Biology of Blood and Marrow Transplantation  
post-HCT (10-pre-HCT and 5-post-HCT) comprising the Imatinib group and the remaining 17-patients, who either never received Imatinib (n 5 13) or received it at time of relapse (n 5 4), were the non-Imatinib group. Overall survival and relapse-free survival at 2 years was 73% and 65% for the Imatinib group compared to 34% and 35% for the non-Imatinib group (p 5 0.14 and 0.1, respectively). However, the incidence of relapse for these two groups was 8% (95% CI: 0.00, 0.24) and 41% (95% CI: 0.17,
more » ... 66), respectively (p 5 0.02). Transplant related mortality at 2-years was similar between groups (27% and 24%; p 5 0.81). Of note, cardiac toxicity [defined as a reduction in left ventricular ejection fraction of .20% below baseline, cardiac hypertrophy or EKG abnormalities (ST changes, T-wave abnormalities, ischemia and/or infarction)] was less in the Imatinib group, 23% (95% CI: 0.00, 0.49) versus 47% (95% CI: 0.22, 0.72) (p 5 0.09). In conclusion, the use of Imatinib therapy in patients with Ph1 ALL in either the pre-or-post-HCT setting decreases the rate of relapse with a trend toward improved RFS and OS. Furthermore, Imatinib treated patients have no obvious increased risk of cardiac toxicity.
doi:10.1016/j.bbmt.2007.12.161 fatcat:s2v7k3mambafxgj7kyge6ayupm